menu
    • menu

    Company profile for Alphamab Oncology

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alphamab Co. Ltd was established in early 2009 by Dr. Ting Xu, recipient of prominent “Thousand Talent Program”. Since its inception, the company has been striving to become a leader in booming biotech industry in China., Alphamab Oncology has built a robust pipeline in oncology/immunology with more than 20 phase II-III clinical trials ongoing, and we are striving to develop next generation and best-in-class medicines to a...
    Alphamab Co. Ltd was established in early 2009 by Dr. Ting Xu, recipient of prominent “Thousand Talent Program”. Since its inception, the company has been striving to become a leader in booming biotech industry in China., Alphamab Oncology has built a robust pipeline in oncology/immunology with more than 20 phase II-III clinical trials ongoing, and we are striving to develop next generation and best-in-class medicines to address unmet medical needs and accessibility globally.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alphamab OncologyChina Flag
    Country
    Country
    China
    Address
    Address
    218 Xinhu St. Building #C23, Suzhou, Jiangsu
    Telephone
    Telephone
    +86-21 5020 0365
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alphamabonc.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    China’s CDE Approves Alphamab’s JSKN033 Phase I/II Trial
    China’s CDE Approves Alphamab’s JSKN033 Phase I/II Trial

    27 Dec 2024

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/china-alphamab-trial-jskn033/

    CLINICAL TRIALS ARENA
    27 Dec 2024
    Share Share
    Alphamab to Present Chinese Clinical Data of JSKN003 for HER2-exp. Solid Tumors
    Alphamab to Present Chinese Clinical Data of JSKN003 for HER2-exp. Solid Tumors

    06 May 2024

    // ASIAONE

    https://www.asiaone.com/business/alphamab-oncology-present-chinese-clinical-data-jskn003-treatment-her2-expressing-solid

    ASIAONE
    06 May 2024
    Share Share
    Alphamab Oncology Reports Full Year 2021 Financial Results
    Alphamab Oncology Reports Full Year 2021 Financial Results

    30 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/first-year-of-commercialization-alphamab-oncology-reports-full-year-2021-financial-results-and-business-highlights-301513446.html

    PRNEWSWIRE
    30 Mar 2022
    Share Share
    IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026
    IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026

    05 Jan 2022

    // ASIAONE

    https://www.asiaone.com/business/ind-approved-pivotal-clinical-study-her2-bispecific-antibody-kn026-combined-chemotherapy

    ASIAONE
    05 Jan 2022
    Share Share
    Alphamab Announces First Patient Dosed in the Pivotal Clinical Study of KN046
    Alphamab Announces First Patient Dosed in the Pivotal Clinical Study of KN046

    29 Oct 2021

    // ALPHAMABONC

    http://www.alphamabonc.com/en/html/news/2365.html

    ALPHAMABONC
    29 Oct 2021
    Share Share
    Alphamab partners in $150m licensing deal; Pfizer to join lawsuit on tariffs
    Alphamab partners in $150m licensing deal; Pfizer to join lawsuit on tariffs

    26 Aug 2021

    // P. Schloesser ENDPTS

    https://endpts.com/chinese-pharma-groups-partner-in-150m-licensing-deal-pfizer-to-join-lawsuit-on-tariffs/

    P. Schloesser ENDPTS
    26 Aug 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search